A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A

被引:71
作者
Bouma, M
Nuijen, B
Jansen, MT
Sava, G
Flaibani, A
Bult, A
Beijnen, JH
机构
[1] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
[2] Fdn Callerio, I-34127 Trieste, Italy
[3] SIGEA Srl, I-34012 Trieste, Italy
[4] Univ Utrecht, Fac Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands
关键词
NAMI-A; chemical stability; high performance liquid chromatography (HPLC);
D O I
10.1016/S0378-5173(02)00460-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
NAMI-A is a novel ruthenium complex with selective activity against cancer metastases currently in Phase I clinical trials in The Netherlands. The chemical stability of this new agent was investigated utilizing a stability-indicating reversed-phase high performance liquid chromatographic assay with ultraviolet detection and ultraviolet/visible light spectrophotometry. The degradation kinetics of NAMI-A were studied as a function of pH, buffer composition, and temperature. Degradation of NAMI-A follows first-order kinetics at pH < 6 and zero-order kinetics at pH greater than or equal to 6. A pH-rate profile, employing rate constants extrapolated to zero buffer concentration, was constructed, demonstrating that NAMI-A is most stable in pH region 3-4. The degradation rate is not significantly affected by specific buffer components. Storage temperature strongly influences the degradation rate. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:239 / 246
页数:8
相关论文
共 15 条
[1]   Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells [J].
Bergamo, A ;
Zorzet, S ;
Gava, B ;
Sorc, A ;
Alessio, E ;
Iengo, E ;
Sava, G .
ANTI-CANCER DRUGS, 2000, 11 (08) :665-672
[2]  
Bergamo A, 1999, J PHARMACOL EXP THER, V289, P559
[3]  
BOUMA M, 2002, IN PRESS J PHARM BIO
[4]   Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice [J].
Cocchietto, M ;
Sava, G .
PHARMACOLOGY & TOXICOLOGY, 2000, 87 (05) :193-197
[5]  
MARTIN A, 1993, PHYSICAL PHARM, pCH12
[6]  
Mestroni G, 1994, Met Based Drugs, V1, P41
[7]  
Sava G, 1999, ANTICANCER RES, V19, P969
[8]  
Sava G, 1998, CLIN EXP METASTAS, V16, P371
[9]  
Sava G, 2000, CLIN CANCER RES, V6, p4566S
[10]   Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]:: mechanism of the selective action investigated on mouse tumors [J].
Sava, G ;
Clerici, K ;
Capozzi, I ;
Cocchietto, M ;
Gagliardi, R ;
Alessio, E ;
Mestroni, G ;
Perbellini, A .
ANTI-CANCER DRUGS, 1999, 10 (01) :129-138